Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 137173A

Drug Profile

GSK 137173A

Alternative Names: GSK 1437173A; GSK137173A; Herpes zoster vaccine candidate (Hz/su) - GSK; PED-HZ/su; QS-21 containing herpes zoster vaccine - GSK/Agenus; recombinant adjuvanted Herpes Zoster vaccine; Shingrix; Varicella zoster vaccine - GSK; Varicella zoster virus vaccine - GSK; VZV gE; VZV vaccine - GSK/Agenus

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK; Japan Vaccine
  • Class Subunit vaccines; Synthetic vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster

Most Recent Events

  • 26 Jul 2023 Launched for Herpes zoster (Prevention) in Japan (IM)
  • 26 Jul 2023 Registered for Herpes zoster (Prevention) in Japan (IM)
  • 28 Jun 2023 GlaxoSmithKline Biologicals completes the follow-up phase IIIb ZOSTER-049 EXT:006-022 trial for Herpes zoster (Prevention) in USA, Australia, Brazil, Canada, France, Hong Kong, Italy, Japan, South Korea, Mexico, Sweden, Taiwan, Estonia, Finland, Czech Republic, Germany, Spain and the UK (IM) (EudraCT2015-001778-17) (NCT02723773)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top